复发头颈癌症状与临床发现同预期结局的关联
该回顾性队列研究纳入196例复发头颈癌患者,用两种多变量技术构建综合分期系统预测1年总生存。新系统将患者分为A、B、C三组,1年OS分别为90.2%、58.1%、18.4%,区分能力优于AJCC分期(C=0.79 vs 0.66)。
要点
- 复发头颈癌1年总生存为58.2%。
- 综合临床严重度分期可区分三组预后。
- 新分期区分能力优于AJCC分期。
核心结论
- 临床变量与复发头颈癌患者的预期结局相关。
- 综合分期系统可预测1年总生存且区分能力优于AJCC。
研究设计与样本
- 回顾性队列研究,纳入2007至2014年Siteman癌症中心根治性治疗后复发的196例患者。
- 采用序贯分离与联合整合两种多变量技术构建综合分期系统。
主要发现
- 196例患者平均年龄61岁(SD 11),男性占76.5%,白人占84.7%。
- 1年总生存为58.2%(114/196)。
- A组61例1年OS为90.2%(95%CI 82.7%-97.6%)。
- B组86例1年OS为58.1%(95%CI 47.7%-68.6%)。
- C组49例1年OS为18.4%(95%CI 7.5%-29.2%)。
关键数值与推荐
- 综合分期纳入复发时间、症状严重度分期和rTNM分期。
- 新综合分期区分能力C=0.79,AJCC分类C=0.66。
临床怎么用
- 可利用症状和临床变量对复发头颈癌患者进行预后分层与咨询。
- 综合分期可能比AJCC分期更准确预测1年生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Despite advances in treatment over the last decades, recurrent head and neck cancer continues to have a poor prognosis. Prognostic accuracy may help in patient counseling. OBJECTIVE: To explore whether symptoms and clinical variables can predict prognosis in the setting of recurrent head and neck cancer. DESIGN, SETTING, AND PARTICIPANTS: In this retrospective cohort study, patients treated for head and neck cancer with curative intent at Siteman Cancer Center in St Louis, Missouri (a tertiary cancer center) between January 1, 2007, and December 31, 2014, were reviewed. The dates of data analysis were October 2016 to June 2017. Patients who developed a recurrent cancer were included, with 196 patients meeting inclusion criteria. MAIN OUTCOMES AND MEASURES: Symptoms and clinical findings at presentation of recurrence were recorded. Sequential sequestration and conjunctive consolidation (2 multivariable techniques) were used to create a composite staging system to predict 1-year overall survival (OS). RESULTS: Among 196 patients (mean [SD] age, 61 [11] years; 166 [84.7%] of white race/ethnicity; 76.5% male), 1-year OS was 58.2% (114 of 196 patients). Time to recurrence, symptom severity stage, and rTNM stage were consolidated into a 3-category Clinical Severity Staging System, with 1-year OS rates of 90.2% (95% CI, 82.7%-97.6%) for the 61 patients classified as A, 58.1% (95% CI, 47.7%-68.6%) for the 86 patients classified as B, and 18.4% (95% CI, 7.5%-29.2%) for the 49 patients classified as C. The discriminative power of the new composite staging was better than that of the American Joint Committee on Cancer classification (C = 0.79 vs C = 0.66). CONCLUSIONS AND RELEVANCE: These findings suggest that clinical variables are associated with anticipated outcomes in patients with recurrent head and neck cancer.
引用
- Pipkorn P, Licata J, Kallogjeri D, et al. Association of Symptoms and Clinical Findings With Anticipated Outcomes in Patients With Recurrent Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg. 2018. PMID: 30003215. doi:10.1001/jamaoto.2018.1230
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。